The significant anti-cancer therapeutic potential is revealed by studies in which CD133 was targeted in lung cancer (Bertolini et al., 2009), liver cancer (Rountree et al., 2009), and glioblastoma (Brescia et al., 2013). This evidence concerns the gene PROM1 and lung cancer.